RecruitingNCT04161066
Safety study of psilocybin with buprenorphine for opioid use disorder
About this title
Read the official source — NCT04161066Medication studyAges 21–65United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 21 years to 65 years.
- Listed locations
- MadisonSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 13, 2021
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 10
- Sponsor
- University of Wisconsin, Madison
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 21 Years to 65 Years
- Official registry ID
- NCT04161066
- Official title
Show the full official title
Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation
Recruitment & locations
RecruitingMadison
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is University of Wisconsin, Madison, a university.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin with facilitated counseling.
Who can participate?
Listed age limits: 21 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
